Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poractant alfa (Curosurf) bronchoscopy-directed administration in COVID-19 ARDS
2020-001598-66Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute respiratory distress syndrome (ARDS) and coronavirus pneumonia comparing Poractant alfa plus standard of care with Standard of care (2 arms). Primary endpoint: Primary outcome: change in PaO2/FiO2 ratio. Started Apr 2020; status: completed.
02
Drugs
Poractant alfa
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001598-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001598-66.